FLT1
Vascular endothelial growth factor receptor 1
Also known as: FLT, VEGFR1, VGFR1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17948
- Gene
- FLT1
- Ensembl
- ENSG00000102755
- Chromosome
- 13
- Canonical length
- 1338 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins
- Subcellular location
- Plasma membrane,Actin filaments,Cytosol
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.[provided by RefSeq, May 2009]
Canonical amino-acid sequenceUniProt
1338 residues, UniProt reviewed canonical sequence.
>P17948|FLT1
1 MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK
61 WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET
121 ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD
181 GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV
241 KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK
301 MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
361 AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
421 TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC
481 DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
541 VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM
601 HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA
661 PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
721 VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI
781 RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK
841 VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
901 QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
961 TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
1021 RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
1081 DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
1141 PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA
1201 PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW
1261 TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC
1321 CSPPPDYNSV VLYSTPPILocalizationUniProt · AlphaFold · HPA
Whether an antibody against FLT1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 394 nTPM
Expression across tissuesHPA
Tissue
- placenta: 394 nTPM
- retina: 46 nTPM
- adipose tissue: 45 nTPM
- thyroid gland: 45 nTPM
- heart muscle: 44 nTPM
- tongue: 36 nTPM
Single-cell type
- syncytiotrophoblasts: 1,704 nCPM
- extravillous trophoblasts: 1,645 nCPM
- vascular endothelial cells: 1,219 nCPM
- müller glia: 546 nCPM
- migrating cytotrophoblasts: 450 nCPM
- cytotrophoblasts: 309 nCPM
Immune cell
- naive B-cell: 0.8 nTPM
- neutrophil: 0.5 nTPM
- memory B-cell: 0.3 nTPM
- plasmacytoid DC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
Brain region
- thalamus: 85 nTPM
- pons: 68 nTPM
- cerebral cortex: 58 nTPM
- medulla oblongata: 58 nTPM
- hypothalamus: 53 nTPM
- midbrain: 53 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FLT1.
Disease | ImmuneIEDB
Conditions an epitope on FLT1 was assayed in.
- renal cell carcinoma T cell
- high grade glioma T cell
- cervical cancer T cell
- brain glioma T cell
- gastric adenocarcinoma T cell
- pancreatic adenocarcinoma T cell
- esophagus squamous cell carcinoma T cell
- lung non-small cell carcinoma T cell
- cholangiocarcinoma T cell
- colorectal cancer T cell
ReferencesPubMed · IEDB
Publications for FLT1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Dysregulation of circulating autoantibodies against VEGF-A, VEGFR-1 and PlGF in preeclampsia - A role in placental and vascular health?
2017 · Pregnancy Hypertens · RCR 0.6 · 13 citations
Reference: T cellIEDB
12 publications
- A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
2014 · J Transl Med · RCR 2 · 72 citations - Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
2014 · J Transl Med · RCR 2 · 80 citations - Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
2012 · Int J Oncol · RCR 1.6 · 67 citations - Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
2013 · J Transl Med · RCR 1.6 · 63 citations - Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
2017 · Cancer Sci · RCR 1.5 · 54 citations
Show 7 more
- Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.
2017 · Int J Oncol · RCR 1.4 · 48 citations - A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma.
2019 · J Clin Med · RCR 0.9 · 23 citations - Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.
2013 · Br J Cancer · RCR 0.9 · 36 citations - A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.
2018 · Oncotarget · RCR 0.8 · 22 citations - Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
2018 · J Immunother · RCR 0.8 · 24 citations - Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
2018 · Liver Int · RCR 0.4 · 14 citations - P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
2014 · Cancer Immunol Immunother · RCR 0.3 · 13 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.25
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.45
- DepMap mean gene effect
- 0
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- blood vessel morphogenesis
- cell differentiation
- cell migration
- cell surface receptor protein tyrosine kinase signaling pathway
- cellular response to vascular endothelial growth factor stimulus
- embryonic morphogenesis
- hyaloid vascular plexus regression
- monocyte chemotaxis
- negative regulation of vascular endothelial cell proliferation
- peptidyl-tyrosine phosphorylation
- positive regulation of angiogenesis
- positive regulation of cell migration
- positive regulation of cell population proliferation
- positive regulation of MAP kinase activity
- positive regulation of MAPK cascade
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- protein autophosphorylation
- sprouting angiogenesis
- vascular endothelial growth factor receptor signaling pathway
- vascular endothelial growth factor receptor-1 signaling pathway
Molecular functions
- ATP binding
- growth factor binding
- transmembrane receptor protein tyrosine kinase activity
- vascular endothelial growth factor receptor activity
- placental growth factor receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Serine-threonine/tyrosine-protein kinase, catalytic domain
- Tyrosine-protein kinase, receptor class III, conserved site
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Immunoglobulin-like domain
- Tyrosine-protein kinase, active site
- Protein kinase-like domain superfamily
- Immunoglobulin I-set
- Immunoglobulin V-set domain
- Immunoglobulin-like beta-sandwich domain
- Immunoglobulin-like fold
- Protein kinase, ATP binding site
- Tyrosine-protein kinase, catalytic domain
- Immunoglobulin-like domain superfamily
- VEGFR-2, transmembrane domain
- Receptor Tyrosine Kinase
- VEGFR1-3, fifth immunoglobulin-like domain
- VEGFR1-3-like, N-terminal Ig-like domain
- Immunoglobulin domain
- Immunoglobulin I-set domain
- Protein tyrosine and serine/threonine kinase
- Immunoglobulin domain
- VEGFR-2 Transmembrane domain
- Vascular endothelial growth factor receptor 1-like, Ig-like domain
- VEGFR1-3, N-terminal Ig-like domain
- VEGFR-1-like, immunoglobulin-like domain
- Vascular endothelial growth factor receptor 1 (VEGFR1)
KeywordsUniProt
- Angiogenesis
- ATP-binding
- Cell membrane
- Chemotaxis
- Cytoplasm
- Developmental protein
- Differentiation
- Disulfide bond
- Endosome
- Glycoprotein
- Immunoglobulin domain
- Kinase
- Membrane
- Nucleotide-binding
- Phosphoprotein
- Receptor
- Repeat
- Secreted
- Signal
- Transferase
- Transmembrane
- Transmembrane helix
- Tyrosine-protein kinase
- Ubl conjugation
InteractionsUniProt · HPA
Protein binding partners of FLT1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FLT1 as an antibody target. Whether an autoantibody or antibody against FLT1 could matter depends on whether native FLT1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FLT1 is annotated at the cell surface, where native FLT1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label FLT1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...